Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Convertible Debt (2016 - 2017)

Historic Convertible Debt for Lineage Cell Therapeutics (LCTX) over the last 4 years, with Q4 2017 value amounting to $1.9 million.

  • Lineage Cell Therapeutics' Convertible Debt rose 8071.71% to $1.9 million in Q4 2017 from the same period last year, while for Dec 2017 it was $1.9 million, marking a year-over-year increase of 8071.71%. This contributed to the annual value of $1.9 million for FY2017, which is 8071.71% up from last year.
  • Latest data reveals that Lineage Cell Therapeutics reported Convertible Debt of $1.9 million as of Q4 2017, which was up 8071.71% from $1.1 million recorded in Q1 2017.
  • In the past 5 years, Lineage Cell Therapeutics' Convertible Debt ranged from a high of $1.9 million in Q4 2017 and a low of $60000.0 during Q4 2014
  • Over the past 4 years, Lineage Cell Therapeutics' median Convertible Debt value was $617908.0 (recorded in 2015), while the average stood at $741132.4.
  • In the last 5 years, Lineage Cell Therapeutics' Convertible Debt soared by 44000.0% in 2015 and then plummeted by 2632.98% in 2016.
  • Over the past 4 years, Lineage Cell Therapeutics' Convertible Debt (Quarter) stood at $60000.0 in 2014, then surged by 440.0% to $324000.0 in 2015, then surged by 218.52% to $1.0 million in 2016, then skyrocketed by 80.72% to $1.9 million in 2017.
  • Its Convertible Debt was $1.9 million in Q4 2017, compared to $1.1 million in Q1 2017 and $1.0 million in Q4 2016.